In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weider is now Schiff

This article was originally published in The Tan Sheet

Executive Summary

Weider Nutrition International formally changes name to Schiff Nutrition International following a shareholder vote of approval Oct. 25, the firm announces. "The Schiff brand is a recognized premium brand in the nutritional supplements arena, and it is appropriate that our new corporate name reflects our strategic commitment to growing the Schiff brand," President and CEO Bruce Wood said. The firm divested the Weider brand business last year, and its European subsidiary Haleko in June (1"The Tan Sheet" Aug. 23, 2004, p. 12 and 2"The Tan Sheet" June 27, 2005, In Brief). While the firm will start trading on the New York Stock exchange under the new name Nov. 1, WNI will remain the company's N.Y. Stock Exchange symbol....

You may also be interested in...



Follow The Weider: Analysts Glance Askance At Weider Brand Sale

Weider Nutrition International's sale of its namesake branded nutritionals to the company's majority stockholder is raising some concerns in the investment community

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS098788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel